Eton Pharmaceuticals has acquired the rights to develop and commercialize the Zeneo needle-free autoinjector in the United States and Canada from Crossject. The device is designed to administer the drug Hydrocortisone for the treatment of adrenal insufficiency under development. Crossject will receive about $11 million from Eton, as well as a 10% royalty on net sales of the product.